Targacept to Present at the Stifel Healthcare Conference 2013

  Targacept to Present at the Stifel Healthcare Conference 2013

Stifel Nicolaus 2013 Global Healthcare Conference

Business Wire

WINSTON-SALEM, N.C. -- September 5, 2013

Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company
developing novel NNR Therapeutics (TM), today announced that Dr. Stephen A.
Hill, President and Chief Executive Officer, is scheduled to present at the
Stifel Healthcare Conference 2013 at the Four Seasons Hotel Boston on
Thursday, September 12, 2013 at 8:35 a.m. Eastern Time.

The presentation will be webcast and accessible from the Investor Relations
page of Targacept’s website, www.targacept.com. To ensure a timely connection
to the webcast, it is recommended that users register at least 15 minutes
prior to the scheduled start time. An archived version of the webcast will be
available for replay on the Investor Calendar section of the Investor
Relations page of Targacept’s website for at least two weeks following the

About Targacept

Targacept is developing an advanced clinical pipeline of NNR Therapeutics™ to
treat patients suffering from serious nervous system and
gastrointestinal/genitourinary diseases and disorders. Many diseases arise
from abnormalities in signaling within and between the brain and other organ
systems such as the bladder and the GI tract. Targacept’s NNR Therapeutics
have the potential to normalize these signaling pathways to provide
significant medical benefit. Targacept is dedicated to building health and
restoring independence for patients. For more information, please visit

Building Health, Restoring Independence^®


Targacept, Inc.
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
Linnden Communications
Michelle Linn, 508-362-3087
Press spacebar to pause and continue. Press esc to stop.